Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 9 | 2023 | 555 | 2.010 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 99 | 0.790 |
Why?
|
| Blood Platelets | 3 | 2011 | 252 | 0.690 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 82 | 0.660 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 182 | 0.650 |
Why?
|
| Comorbidity | 1 | 2017 | 617 | 0.490 |
Why?
|
| Melphalan | 1 | 2015 | 173 | 0.460 |
Why?
|
| Leukocytes | 2 | 2011 | 69 | 0.460 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 54 | 0.450 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 60 | 0.450 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2014 | 56 | 0.450 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 164 | 0.430 |
Why?
|
| Hemagglutination Tests | 1 | 2011 | 7 | 0.390 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 73 | 0.380 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 25 | 0.380 |
Why?
|
| Isoantibodies | 1 | 2011 | 27 | 0.380 |
Why?
|
| Transplantation, Autologous | 4 | 2015 | 464 | 0.370 |
Why?
|
| Plateletpheresis | 1 | 2010 | 7 | 0.360 |
Why?
|
| Blood Preservation | 1 | 2010 | 26 | 0.360 |
Why?
|
| Cryopreservation | 1 | 2010 | 31 | 0.350 |
Why?
|
| Blood Proteins | 1 | 2010 | 77 | 0.350 |
Why?
|
| Anaphylaxis | 1 | 2010 | 70 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1003 | 0.320 |
Why?
|
| Rhabdomyolysis | 1 | 2008 | 12 | 0.310 |
Why?
|
| Simvastatin | 1 | 2008 | 29 | 0.300 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 28 | 0.300 |
Why?
|
| Quinazolines | 1 | 2008 | 32 | 0.300 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 2949 | 0.300 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 11 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 205 | 0.270 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 162 | 0.260 |
Why?
|
| Pyrazoles | 2 | 2023 | 111 | 0.250 |
Why?
|
| Aged | 8 | 2024 | 9590 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 634 | 0.230 |
Why?
|
| Time Factors | 1 | 2010 | 2934 | 0.230 |
Why?
|
| Humans | 16 | 2024 | 50389 | 0.230 |
Why?
|
| Acetamides | 1 | 2023 | 18 | 0.220 |
Why?
|
| Adult | 8 | 2024 | 13568 | 0.220 |
Why?
|
| Platelet Transfusion | 2 | 2015 | 28 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2024 | 6223 | 0.210 |
Why?
|
| Antigens, CD34 | 2 | 2011 | 65 | 0.180 |
Why?
|
| Middle Aged | 6 | 2024 | 12460 | 0.180 |
Why?
|
| Cell Count | 2 | 2011 | 147 | 0.180 |
Why?
|
| Graft Survival | 2 | 2011 | 153 | 0.180 |
Why?
|
| Heart Rate | 1 | 2021 | 311 | 0.170 |
Why?
|
| Cell Survival | 2 | 2011 | 590 | 0.160 |
Why?
|
| Incidence | 1 | 2021 | 1017 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2020 | 155 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 35 | 0.140 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 140 | 0.140 |
Why?
|
| Appendicitis | 1 | 2017 | 62 | 0.140 |
Why?
|
| Young Adult | 3 | 2024 | 4064 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 396 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 74 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2016 | 133 | 0.130 |
Why?
|
| Carmustine | 1 | 2015 | 13 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 52 | 0.120 |
Why?
|
| Cytarabine | 1 | 2015 | 40 | 0.120 |
Why?
|
| Etoposide | 1 | 2015 | 71 | 0.120 |
Why?
|
| Bronchoscopy | 1 | 2015 | 70 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 84 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2015 | 136 | 0.120 |
Why?
|
| Survival Rate | 1 | 2017 | 915 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2014 | 9 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 450 | 0.110 |
Why?
|
| Blood Cell Count | 1 | 2014 | 38 | 0.110 |
Why?
|
| Drug Evaluation | 1 | 2014 | 28 | 0.110 |
Why?
|
| Benzylamines | 1 | 2014 | 15 | 0.110 |
Why?
|
| Heterocyclic Compounds | 1 | 2014 | 29 | 0.110 |
Why?
|
| Male | 7 | 2024 | 25718 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2014 | 152 | 0.110 |
Why?
|
| Female | 6 | 2024 | 26981 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2017 | 1258 | 0.100 |
Why?
|
| Nitriles | 2 | 2023 | 52 | 0.100 |
Why?
|
| Prognosis | 1 | 2017 | 1979 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 2011 | 84 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 487 | 0.090 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2010 | 12 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2023 | 193 | 0.090 |
Why?
|
| Isotonic Solutions | 1 | 2010 | 18 | 0.090 |
Why?
|
| P-Selectin | 1 | 2010 | 32 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2010 | 58 | 0.090 |
Why?
|
| Platelet Aggregation | 1 | 2010 | 71 | 0.090 |
Why?
|
| Platelet Activation | 1 | 2010 | 47 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 2010 | 75 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2011 | 386 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 875 | 0.080 |
Why?
|
| Atenolol | 1 | 2008 | 14 | 0.080 |
Why?
|
| Azetidines | 1 | 2008 | 6 | 0.080 |
Why?
|
| Amlodipine | 1 | 2008 | 14 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 52 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2008 | 208 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 127 | 0.070 |
Why?
|
| Aspirin | 1 | 2008 | 111 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 122 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 152 | 0.070 |
Why?
|
| Antigens, CD19 | 1 | 2024 | 27 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 277 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2024 | 5230 | 0.060 |
Why?
|
| Adolescent | 2 | 2024 | 6475 | 0.050 |
Why?
|
| Hypertension | 1 | 2008 | 550 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 1160 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 600 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2023 | 570 | 0.050 |
Why?
|
| Child | 1 | 2011 | 6877 | 0.040 |
Why?
|
| Ganciclovir | 1 | 2017 | 24 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 85 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2017 | 168 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 74 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 180 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2016 | 356 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 592 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 460 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1178 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 3180 | 0.020 |
Why?
|